Clinical trials: System Safety
Multiple Myeloma, Refractory
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific…
- Trial name
- NCT06242249
- Testing
- Anti-BCMA CAR-NK
- Where
- Iran
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Nonalcoholic Steatohepatitis
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single-and multiple-oral doses of ZSP0678 on fasted condition, and characterize PK of ZSP0678 on an empty stomach (fasted condition) and…
- Trial name
- NCT04137055
- Testing
- ZSP0678-10mg, ZSP0678-30mg, ZSP0678-60mg
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Anesthesia, Analgesia
The Efficacy and Safety of S-ketamine in Elective Cesarean Section
During the past years, a large number of clinical trials have investigated the use of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist racemic ketamine as an adjunct to local anaesthetics, opioids, or other…
- Conditions
- Anesthesia, Analgesia, Depression, Cesarean Section
- Trial name
- ES-CS (NCT04657107)
- Testing
- S-ketamine, normal saline
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Beijing Obstetrics and Gynecology Hospital
Huntington Disease
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease
This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the…
- Trial name
- NCT01602900
- Testing
- GSK356278, Rolipram
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Short Bowel Syndrome
Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome
Rotavirus infection is a common pediatric illness and is the leading cause of severe acute gastroenteritis (vomiting and diarrhea) in infants and young children.
- Trial name
- NCT00767364
- Testing
- Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Michigan
Catheter Complications
SmartPICC-1 Feasibility Study Technical Feasibility Study
The primary objective of this study is to evaluate the safety and technical feasibility of the Piccolo Medical SmartPICC System, indicated for guidance and positioning of commercially available central venous catheters, for PICC…
- Trial name
- NCT05548192
- Testing
- SmartPICC-1 System
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Piccolo Medical
HIV Infections
A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
To determine if intravenous (IV) and oral zidovudine (AZT) can be safely given to children aged 1 day to 3 months who were born to mothers with an HIV infection. Also to determine the correct dose of AZT for young children.
- Trial name
- NCT00001007
- Testing
- Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers (HV), Parkinson's Disease (PD)
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD).
- Trial name
- NCT07310264
- Testing
- VT-5006
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Vertero Therapeutics
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
NASH
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study.
- Trial name
- NCT06705998
- Testing
- BAR502 single dose, BAR502 multiple doses
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Immune System Diseases, Autoimmune Diseases
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
To evaluate safety, tolerability, pharmacokinetics and immunogenicity of CDP7657
- Conditions
- Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases
- Trial name
- NCT01093911
- Testing
- CDP7657
- Where
- 8 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
This is a Phase 1, single-center study conducted in 2 parts: Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts.
- Trial name
- NCT05795907
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sanofi
Asthma
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers
The objective of this study is to evaluate the pharmacokinetics (PK) and safety profiles of A006, an Albuterol dry powder inhaler (DPI), following a single dose of 110 mcg (T1) or 220 mcg (T2), in healthy male and female adult…
- Trial name
- A006-D (NCT02271334)
- Testing
- A006 DPI, Proventil® MDI
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Immunisation, Shigella Infection
Phase 2 Shigella Vaccine and Challenge
This is a trial to evaluate the safety, reactogenicity, immunogenicity and efficacy of a 10^6 cfu dose of an oral live-attenuated S.
- Trial name
- NCT04242264
- Testing
- Shigella sonnei strain 53G, WRSs2
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes
UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes
The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes
- Trial name
- NCT06751199
- Testing
- human umbilical cord mesenchymal stem cells, allogeneic islet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Migraine With Aura, Migraine Without Aura
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT03874832
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Type 2 Diabetes
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Objective Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
- Trial name
- NCT05113693
- Testing
- CKD-393, CKD-501, D759, H053
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hepatocellular Carcinoma
Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
There are limited treatment options for HCC with high recurrence risk, and there is no consistent plan for adjuvant therapy after surgery. Hence an unmet clinical need.
- Trial name
- NCT05546619
- Testing
- HIPEC+tislelizumab + targeted therapy
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Alzheimer Disease
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the…
- Trial name
- NCT06535308
- Testing
- BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mg
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- BnH Research
Contraception
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol
The purpose of this study is to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal contraceptive system, norelgestromine and ethinyl estradiol (NLGM / EE).
- Trial name
- NCT00307632
- Testing
- Norelgestromine (NLGM)/ethinyl estradiol (EE)
- Where
- 12 sites in Brazil, Mexico
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.